ArticleJournal for immunotherapy of cancer2026

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer.

Julia C F Quintanilha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.